Neurocrine Biosciences, Inc. (NBIX)
146.15
-0.23
(-0.16%)
USD |
NASDAQ |
Oct 30, 16:00
146.15
0.00 (0.00%)
After-Hours: 20:00
Neurocrine Biosciences Cash from Investing (Quarterly) : -135.40M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -135.40M |
| March 31, 2026 | -506.20M |
| December 31, 2025 | -52.90M |
| September 30, 2025 | -196.70M |
| June 30, 2025 | -29.00M |
| March 31, 2025 | 14.20M |
| December 31, 2024 | -68.30M |
| September 30, 2024 | 24.70M |
| June 30, 2024 | -28.20M |
| March 31, 2024 | -55.00M |
| December 31, 2023 | -201.80M |
| September 30, 2023 | -97.30M |
| June 30, 2023 | -125.90M |
| March 31, 2023 | -42.10M |
| December 31, 2022 | -115.60M |
| September 30, 2022 | -61.30M |
| June 30, 2022 | 31.40M |
| March 31, 2022 | -31.60M |
| December 31, 2021 | 23.70M |
| September 30, 2021 | -126.20M |
| June 30, 2021 | -90.80M |
| March 31, 2021 | 63.10M |
| December 31, 2020 | -147.70M |
| September 30, 2020 | 25.20M |
| June 30, 2020 | 93.40M |
| Date | Value |
|---|---|
| March 31, 2020 | 33.20M |
| December 31, 2019 | -166.16M |
| September 30, 2019 | -85.65M |
| June 30, 2019 | -0.243M |
| March 31, 2019 | 40.97M |
| December 31, 2018 | -106.26M |
| September 30, 2018 | -45.10M |
| June 30, 2018 | -34.51M |
| March 31, 2018 | -57.05M |
| December 31, 2017 | -59.01M |
| September 30, 2017 | -35.39M |
| June 30, 2017 | -213.11M |
| March 31, 2017 | 56.65M |
| December 31, 2016 | 15.07M |
| September 30, 2016 | 43.20M |
| June 30, 2016 | -15.66M |
| March 31, 2016 | 70.26M |
| December 31, 2015 | 22.01M |
| September 30, 2015 | -47.86M |
| June 30, 2015 | -53.91M |
| March 31, 2015 | -116.09M |
| December 31, 2014 | 15.54M |
| September 30, 2014 | 3.216M |
| June 30, 2014 | -58.40M |
| March 31, 2014 | -65.73M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Amgen, Inc. | -569.00M |
| Halozyme Therapeutics, Inc. | -62.66M |
| BioCryst Pharmaceuticals, Inc. | -110.15M |
| Precigen, Inc. | 26.69M |
| BioMarin Pharmaceutical, Inc. | -5.102B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 78.00M |
| Cash from Financing (Quarterly) | 121.80M |
| Free Cash Flow | 812.00M |
| Free Cash Flow Per Share (Quarterly) | 0.6737 |
| Free Cash Flow to Equity (Quarterly) | 74.60M |
| Free Cash Flow to Firm (Quarterly) | 72.78M |
| Free Cash Flow Yield | 5.37% |